{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:03:04Z","timestamp":1781326984192,"version":"3.54.1"},"reference-count":86,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autoimmune hemolytic anemia (AIHA) is an uncommon entity that presents diagnostic, prognostic, and therapeutic dilemmas despite being a well-recognized entity for over 150 years. This is because of significant differences in the rates of hemolysis and associated diseases and because there is considerable clinical heterogeneity. In addition, there is a lack of clinical trials required to refine and update standardized and evidence-based therapeutic approaches. To aid the clinician in AIHA management, we present four vignettes that represent and highlight distinct clinical presentations with separate diagnostic and therapeutic pathways that we use in our clinical practice setting. We also review the parameters present in diagnostic testing that allow for prognostic insight and present algorithms for both diagnosis and treatment of the AIHA patient in diverse situations. This is done in the hope that this review may offer guidance in regard to personalized therapy recommendations. A section is included for the diagnosis of suspected AIHA with negative test results, a relatively infrequent but challenging situation, in order to assist in the overall evaluation spectrum for these patients.<\/jats:p>","DOI":"10.1182\/blood-2016-11-693689","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T01:01:33Z","timestamp":1490922093000},"page":"2971-2979","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":154,"title":["How I treat autoimmune hemolytic anemia"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-3732","authenticated-orcid":false,"given":"Jeffrey L.","family":"Winters","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5055","authenticated-orcid":false,"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111903550129300_B1","first-page":"1812","article-title":"\u00dcber Beziehungen zwischen dem Blutserum und den K\u00f6rperzellen","volume":"50","author":"Landsteiner","year":"1903","journal-title":"Munch Med Wochenschr"},{"key":"2019111903550129300_B2","first-page":"1590","article-title":"Uber paroxysmale Hamoglobinurie","volume":"51","author":"Donath","year":"1904","journal-title":"Munch Med Wochenschr"},{"issue":"2","key":"2019111903550129300_B3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0002-9343(67)90168-4","article-title":"Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965","volume":"43","author":"Allgood","year":"1967","journal-title":"Am J Med"},{"issue":"3","key":"2019111903550129300_B4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/tm.2000.7392","article-title":"Autoimmune hemolytic anemia: a history","volume":"14","author":"Mack","year":"2000","journal-title":"Transfus Med Rev"},{"issue":"4","key":"2019111903550129300_B5","first-page":"255","article-title":"A new test for the detection of weak and incomplete Rh agglutinins","volume":"26","author":"Coombs","year":"1945","journal-title":"Br J Exp Pathol"},{"issue":"1","key":"2019111903550129300_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","article-title":"Epidemiology of autoimmune diseases in Denmark","volume":"29","author":"Eaton","year":"2007","journal-title":"J Autoimmun"},{"issue":"5","key":"2019111903550129300_B7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3324\/haematol.2010.036053","article-title":"New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children","volume":"96","author":"Aladjidi","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"2019111903550129300_B8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0248-8663(02)00688-4","article-title":"[Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases]","volume":"23","author":"Genty","year":"2002","journal-title":"Rev Med Interne"},{"issue":"15","key":"2019111903550129300_B9","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1182\/blood-2011-05-347708","article-title":"Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults","volume":"118","author":"Crowther","year":"2011","journal-title":"Blood"},{"key":"2019111903550129300_B10","article-title":"Technical Manual.","author":"Fung","year":"2014","edition":"18th ed"},{"issue":"2","key":"2019111903550129300_B11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21307\/immunohematology-2019-098","article-title":"Drug-induced immune hemolytic anemia: the last 30 years of changes","volume":"30","author":"Arndt","year":"2014","journal-title":"Immunohematology"},{"issue":"2","key":"2019111903550129300_B12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.21307\/immunohematology-2019-100","article-title":"Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007","volume":"30","author":"Garratty","year":"2014","journal-title":"Immunohematology"},{"issue":"4","key":"2019111903550129300_B13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1537-2995.2007.01173.x","article-title":"One center\u2019s experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm","volume":"47","author":"Johnson","year":"2007","journal-title":"Transfusion"},{"issue":"1","key":"2019111903550129300_B14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1034\/j.1600-0609.2003.02846.x","article-title":"Severe IgA-mediated auto-immune haemolytic anaemia in a 48-yr-old woman","volume":"70","author":"Bardill","year":"2003","journal-title":"Eur J Haematol"},{"issue":"2","key":"2019111903550129300_B15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1537-2995.1997.37297203520.x","article-title":"IgA red cell autoantibodies and autoimmune hemolysis","volume":"37","author":"Sokol","year":"1997","journal-title":"Transfusion"},{"issue":"15","key":"2019111903550129300_B16","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1001\/jama.1980.03310150024022","article-title":"Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency","volume":"244","author":"Conley","year":"1980","journal-title":"JAMA"},{"issue":"3","key":"2019111903550129300_B17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V69.3.820.820","article-title":"Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases","volume":"69","author":"Liesveld","year":"1987","journal-title":"Blood"},{"issue":"3","key":"2019111903550129300_B18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000339260","article-title":"Erythropoietin may improve anemia in patients with autoimmune hemolytic anemia associated with reticulocytopenia","volume":"39","author":"Arbach","year":"2012","journal-title":"Transfus Med Hemother"},{"issue":"9","key":"2019111903550129300_B19","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1002\/ajh.23767","article-title":"Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients","volume":"89","author":"Roumier","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111903550129300_B20","first-page":"791","article-title":"Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia","volume":"7","author":"Sallah","year":"2001","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"4","key":"2019111903550129300_B21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1172\/JCI106544","article-title":"Quantitative immunology of immune hemolytic anemia: II. The relationship of cell-bound antibody to hemolysis and the effect of treatment","volume":"50","author":"Rosse","year":"1971","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111903550129300_B22","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.4049\/jimmunol.131.3.1240","article-title":"Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy","volume":"131","author":"Fries","year":"1983","journal-title":"J Immunol"},{"issue":"3","key":"2019111903550129300_B23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111903550129300_B24","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2019111903550129300_B25","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2010-03-259325","article-title":"How I treat autoimmune hemolytic anemias in adults","volume":"116","author":"Lechner","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111903550129300_B26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3324\/haematol.2014.114561","article-title":"Treatment of autoimmune hemolytic anemias","volume":"99","author":"Zanella","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2019111903550129300_B27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2007.08.001","article-title":"Hemolytic anemia due to warm autoantibodies","volume":"22","author":"Packman","year":"2008","journal-title":"Blood Rev"},{"issue":"3","key":"2019111903550129300_B28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111903550129300_B29","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.1997.3203137.x","article-title":"Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type","volume":"98","author":"Meyer","year":"1997","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111903550129300_B30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/archsurg.1985.01390290099017","article-title":"Splenectomy in the treatment of hemolytic anemia","volume":"120","author":"Coon","year":"1985","journal-title":"Arch Surg"},{"issue":"6","key":"2019111903550129300_B31","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.amjsurg.2012.05.030","article-title":"Outcomes and complications after splenectomy for hematologic disorders","volume":"204","author":"Patel","year":"2012","journal-title":"Am J Surg"},{"issue":"2","key":"2019111903550129300_B32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1096-8652(199906)61:2<98::AID-AJH4>3.0.CO;2-G","article-title":"Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease","volume":"61","author":"Akpek","year":"1999","journal-title":"Am J Hematol"},{"issue":"21","key":"2019111903550129300_B33","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood-2015-01-588392","article-title":"The role of rituximab in adults with warm antibody autoimmune hemolytic anemia","volume":"125","author":"Dierickx","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111903550129300_B34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1017\/S0950268897007978","article-title":"Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status","volume":"119","author":"Konradsen","year":"1997","journal-title":"Epidemiol Infect"},{"issue":"16","key":"2019111903550129300_B35","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood-2011-06-363556","article-title":"Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies","volume":"119","author":"Barcellini","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111903550129300_B36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0308-2261(21)00630-5","article-title":"Immune haemolytic disease: the autoimmune haemolytic anaemias","volume":"4","author":"Pirofsky","year":"1975","journal-title":"Clin Haematol"},{"issue":"5","key":"2019111903550129300_B37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000438731","article-title":"Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review","volume":"42","author":"Salama","year":"2015","journal-title":"Transfus Med Hemother"},{"issue":"2","key":"2019111903550129300_B38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2002-01-0087","article-title":"High-dose cyclophosphamide for refractory autoimmune hemolytic anemia","volume":"100","author":"Moyo","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111903550129300_B39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12288-013-0290-z","article-title":"Pulse cyclophosphamide therapy in refractory warm autoimmune hemolytic anemia: a new perspective","volume":"30","author":"Thabet","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"9","key":"2019111903550129300_B40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.7326\/0003-4819-111-9-723","article-title":"Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women","volume":"111","author":"Ahn","year":"1989","journal-title":"Ann Intern Med"},{"issue":"2","key":"2019111903550129300_B41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2141.1993.tb08293.x","article-title":"Danazol in autoimmune haemolytic anaemia","volume":"83","author":"Pignon","year":"1993","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111903550129300_B42","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1365-2141.2002.03430.x","article-title":"Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura","volume":"117","author":"Howard","year":"2002","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111903550129300_B43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies","volume":"14","author":"Reynaud","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2019111903550129300_B44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bjh.12486","article-title":"A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia","volume":"163","author":"Maung","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111903550129300_B45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.7326\/0003-4819-157-1-201206190-00429","article-title":"Red blood cell transfusion: a clinical practice guideline from the AABB*","volume":"157","author":"Carson","year":"2012","journal-title":"Ann Intern Med"},{"issue":"12","key":"2019111903550129300_B46","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111903550129300_B47","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","article-title":"Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"2019111903550129300_B48","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111903550129300_B49","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"issue":"9583","key":"2019111903550129300_B50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"2019111903550129300_B51","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111903550129300_B52","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.1998.16.5.1885","article-title":"Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia","volume":"16","author":"Weiss","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9747","key":"2019111903550129300_B53","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"2019111903550129300_B54","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/oxfordjournals.annonc.a059162","article-title":"Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia","volume":"6","author":"Byrd","year":"1995","journal-title":"Ann. Oncol"},{"issue":"3-4","key":"2019111903550129300_B55","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/10428199809068575","article-title":"Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA)","volume":"29","author":"Chasty","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111903550129300_B56","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1080\/10428190902887563","article-title":"A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia","volume":"50","author":"Kaufman","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111903550129300_B57","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.3324\/haematol.2015.138289","article-title":"Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"101","author":"Vitale","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"2019111903550129300_B58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.23909","article-title":"Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC\/MW and GOELAMS)","volume":"90","author":"Quinquenel","year":"2015","journal-title":"Am J Hematol"},{"issue":"10","key":"2019111903550129300_B59","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/sj.leu.2402676","article-title":"Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia","volume":"16","author":"Gupta","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"2019111903550129300_B60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111903550129300_B61","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"9980","key":"2019111903550129300_B62","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"2019111903550129300_B63","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.revmed.2004.08.001","article-title":"[Cold agglutinins, clinical presentation and significance; retrospective analysis of 58 patients]","volume":"25","author":"Chandesris","year":"2004","journal-title":"Rev Med Interne"},{"issue":"7","key":"2019111903550129300_B64","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2013-02-474437","article-title":"Cold agglutinin disease","volume":"122","author":"Swiecicki","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111903550129300_B65","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"key":"2019111903550129300_B66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/asheducation-2006.1.19","article-title":"Cold hemolytic syndrome","author":"Gertz","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2019111903550129300_B67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"Sch\u00f6llkopf","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111903550129300_B68","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"key":"2019111903550129300_B69","article-title":"The Haemolytic Anaemias: Congenital and Acquired.","author":"Dacie","year":"1960"},{"issue":"2","key":"2019111903550129300_B70","doi-asserted-by":"crossref","first-page":"238","DOI":"10.7326\/0003-4819-106-2-238","article-title":"Cold hemagglutinin disease associated with IgG cold-reactive antibody","volume":"106","author":"Silberstein","year":"1987","journal-title":"Ann Intern Med"},{"issue":"11","key":"2019111903550129300_B71","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1182\/blood.V106.11.3710.3710","article-title":"Long-term follow up of patients with cold agglutinin disease","volume":"106","author":"Go","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2019111903550129300_B72","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1172\/JCI108547","article-title":"The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man","volume":"58","author":"Jaffe","year":"1976","journal-title":"J Clin Invest"},{"issue":"17","key":"2019111903550129300_B73","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111903550129300_B74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1034\/j.1600-0609.2000.9l201.x","article-title":"No response to cladribine in five patients with chronic cold agglutinin disease","volume":"65","author":"Berentsen","year":"2000","journal-title":"Eur J Haematol"},{"issue":"2","key":"2019111903550129300_B75","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12185-015-1775-3","article-title":"Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenstr\u00f6m\u2019s macroglobulinemia with bortezomib","volume":"102","author":"Izumi","year":"2015","journal-title":"Int J Hematol"},{"issue":"16","key":"2019111903550129300_B76","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood-2009-01-196329","article-title":"Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease","volume":"113","author":"R\u00f6th","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111903550129300_B77","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/ccr3.399","article-title":"Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity","volume":"3","author":"Shapiro","year":"2015","journal-title":"Clin Case Rep"},{"issue":"2","key":"2019111903550129300_B78","first-page":"311","article-title":"Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report","volume":"11","author":"Gueli","year":"2013","journal-title":"Blood Transfus"},{"issue":"5","key":"2019111903550129300_B79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1532\/IJH97.E0431","article-title":"Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease","volume":"81","author":"Vassou","year":"2005","journal-title":"Int J Hematol"},{"issue":"5","key":"2019111903550129300_B80","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00277-011-1322-0","article-title":"Successful treatment of IgM-monoclonal gammopathy of undetermined significance associated with cryoglobulinemia and cold agglutinin disease with immunochemotherapy with rituximab, fludarabine, and cyclophosphamide","volume":"91","author":"Bhattacharyya","year":"2012","journal-title":"Ann Hematol"},{"issue":"3","key":"2019111903550129300_B81","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.seminhematol.2005.04.005","article-title":"Immune hemolytic anemia associated with negative routine serology","volume":"42","author":"Garratty","year":"2005","journal-title":"Semin Hematol"},{"issue":"4","key":"2019111903550129300_B82","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bcmd.2013.12.003","article-title":"Direct antiglobulin (\u201cCoombs\u201d) test-negative autoimmune hemolytic anemia: a review","volume":"52","author":"Segel","year":"2014","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"2019111903550129300_B83","doi-asserted-by":"crossref","first-page":"108","DOI":"10.21307\/immunohematology-2019-077","article-title":"Clinical and reference lab characteristics of patients with suspected direct antiglobulin test (DAT)-negative immune hemolytic anemia","volume":"31","author":"Karafin","year":"2015","journal-title":"Immunohematology"},{"issue":"4","key":"2019111903550129300_B84","doi-asserted-by":"crossref","first-page":"156","DOI":"10.21307\/immunohematology-2019-214","article-title":"Attempts to support an immune etiology in 800 patients with direct antiglobulin test-negative hemolytic anemia","volume":"26","author":"Leger","year":"2010","journal-title":"Immunohematology"},{"issue":"2","key":"2019111903550129300_B85","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.23356","article-title":"Characterization of direct antiglobulin test-negative autoimmune hemolytic anemia: a study of 154 cases","volume":"88","author":"Kamesaki","year":"2013","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111903550129300_B86","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2016.03.018","article-title":"IVIG in autoimmune disease - Potential next generation biologics","volume":"15","author":"Zuercher","year":"2016","journal-title":"Autoimmun Rev"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/22\/2971\/1400607\/blood693689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/22\/2971\/1400607\/blood693689.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T23:02:39Z","timestamp":1692745359000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/22\/2971\/36045\/How-I-treat-autoimmune-hemolytic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":86,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-11-693689","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}